- MMPs play a central role in extracellular matrix breakdown in disease processes such as arthritis, glomerulonephritis, tissue ulceration, and tumor cell metastasis. MMP activities are specifically regulated by a family of protein inhibitors designated TIMPs of which three forms (TIMPs-1, -2 and -3) are known. Recent work has identified mutations in TIMP-3 as the cause of a dominant early onset macular degeneration, Sorsby's fundus dystrophy (SFD), in humans. The principal investigator's long-term goals are to elucidate the structural basis and mechanisms by which TIMPs regulate MMP activities and how this can be manipulated to enhance its specificity or is disturbed in pathological condition.
The specific aims of the proposal are as follows: (1) Investigation of the inhibition mechanisms of TIMPs. This will be carried out by site-directed mutagenesis using the N-terminal domain of TIMP-1 (N-TIMP-1) as a prototype. The design of mutants will be based on the information obtained from biochemical studies and a forthcoming crystal structure of the TIMP-1-MMP-3 complex that is being determined by a collaborator, Dr. Wolfram Bode at Max-Planck-Institut in Germany. (2) Isolation of selective inhibitors for specific MMPs. The functional sites identified will be subjected to saturation mutagenesis in N-TIMP-1 displayed on M13 phage and inhibitors with enhanced specificity will be isolated by selection with immobilized MMPS. (3) Determination of the functional properties of TIMP-3 and its domains. TIMP-3 and its two domains will be expressed and characterized with respect to inhibitory action on MMPs and binding to extracellular matrix components. The effect of the SFD mutation on these properties, including possible new covalent interactions, will be assessed. (4) Characterization of TIMP-2 binding to the cell surface, a phenomenon that is related to the activation of progelatinase A (proMMP-2). This will be investigated by characterizing a novel TIMP-2 binding protein expressed on the cell surface. This protein will be isolated, cloned and sequenced. (5) Generation of proteins, mutants and enzyme-inhibitor complexes to provide to collaborators for structural studies of TIMP-MMP interactions by X-ray crystallography and multinuclear NMR spectroscopy. These studies will yield mechanistic and structural information about the interaction of TIMPs and MMPs and new insights into the role of TIMP-2 in regulation of pericellular proteolysis in the extracellular matrix.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR040994-06
Application #
2442814
Study Section
General Medicine A Subcommittee 2 (GMA)
Project Start
1991-09-01
Project End
2001-06-30
Budget Start
1997-07-01
Budget End
1998-06-30
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Kansas
Department
Biochemistry
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Santamaria, Salvatore; Fedorov, Oleg; McCafferty, John et al. (2017) Development of a monoclonal anti-ADAMTS-5 antibody that specifically blocks the interaction with LRP1. MAbs 9:595-602
Chanalaris, Anastasios; Doherty, Christine; Marsden, Brian D et al. (2017) Suramin Inhibits Osteoarthritic Cartilage Degradation by Increasing Extracellular Levels of Chondroprotective Tissue Inhibitor of Metalloproteinases 3. Mol Pharmacol 92:459-468
Yamamoto, Kazuhiro; Santamaria, Salvatore; Botkjaer, Kenneth A et al. (2017) Inhibition of Shedding of Low-Density Lipoprotein Receptor-Related Protein 1 Reverses Cartilage Matrix Degradation in Osteoarthritis. Arthritis Rheumatol 69:1246-1256
Yamamoto, Kazuhiro; Okano, Hiroshi; Miyagawa, Wakako et al. (2016) MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1. Matrix Biol 56:57-73
Watanabe, Kenta; Hirata, Michiko; Tominari, Tsukasa et al. (2016) BA321, a novel carborane analog that binds to androgen and estrogen receptors, acts as a new selective androgen receptor modulator of bone in male mice. Biochem Biophys Res Commun 478:279-285
Zou, Haiyin; Wu, Ying; Brew, Keith (2016) Thermodynamic Basis of Selectivity in the Interactions of Tissue Inhibitors of Metalloproteinases N-domains with Matrix Metalloproteinases-1, -3, and -14. J Biol Chem 291:11348-58
Doherty, Christine M; Visse, Robert; Dinakarpandian, Deendayal et al. (2016) Engineered Tissue Inhibitor of Metalloproteinases-3 Variants Resistant to Endocytosis Have Prolonged Chondroprotective Activity. J Biol Chem 291:22160-22172
Watanabe, Kenta; Hirata, Michiko; Tominari, Tsukasa et al. (2016) The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer. J Biol Chem 291:20891-20899
Ismail, Heba M; Yamamoto, Kazuhiro; Vincent, Tonia L et al. (2015) Interleukin-1 Acts via the JNK-2 Signaling Pathway to Induce Aggrecan Degradation by Human Chondrocytes. Arthritis Rheumatol 67:1826-36
Santamaria, Salvatore; Yamamoto, Kazuhiro; Botkjaer, Kenneth et al. (2015) Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2). Biochem J 471:391-401

Showing the most recent 10 out of 109 publications